Back to Journals » Neuropsychiatric Disease and Treatment » Volume 8

The role of paliperidone extended release for the treatment of bipolar disorder

Authors Marino J, English C, Caballero J, Harrington C

Received 28 January 2012

Accepted for publication 2 March 2012

Published 20 April 2012 Volume 2012:8 Pages 181—189


Review by Single anonymous peer review

Peer reviewer comments 2

Jehan Marino1, Clayton English2, Joshua Caballero1, Catherine Harrington1
1College of Pharmacy, Nova Southeastern University, Fort Lauderdale, FL, 2College of Pharmacy, Albany College of Pharmacy and Health Sciences, Colchester, VT, USA

Background: Bipolar disorder (BD) is a chronic, relapsing, episodic mental illness associated with other psychiatric comorbidities. There is a substantial economic burden with BD, which makes it challenging to treat. The aim of this review is to evaluate the pharmacology, clinical efficacy, and safety data related to paliperidone extended release (ER) for the treatment of BD.
Methods: A literature search was performed from January 1966 through January 2012 using PreMEDLINE, MEDLINE, EMBASE, IPA, and to identify articles in English regarding the pharmacology, clinical efficacy, and safety of paliperidone ER in acute mania or mixed episodes or in the maintenance treatment of BD I.
Results: There are currently three published studies relating to the use of paliperidone ER for the treatment of BD. Two of these evaluated paliperidone ER as monotherapy for acute mania, while the other assessed its role as adjunct with a mood stabilizer.
Conclusion: According to the limited available evidence, paliperidone at higher doses of ER 9–12 mg/day may be a safe and efficacious treatment option for acute episodes of mania in BD. A once-daily dose formulation may improve patient adherence to treatment; however, the cost of paliperidone ER, which is higher than that of generically available second-generation antipsychotics (such as olanzapine and risperidone), and a lack of alternative dosage forms (ie, liquid, intramuscular) compared with other agents may limit its usefulness in the treatment of BD. The role of paliperidone ER as an adjunctive agent or for long-term use requires further investigation.

Keywords: paliperidone ER, bipolar disorder, clinical efficacy, safety

Creative Commons License © 2012 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.